Nota de prensa

Ferrer Selects IQVIA for its Safety and Regulatory Technology Needs

abr. 05, 2022

IQVIA’s innovative SaaS solutions deliver pharmacovigilance and regulatory efficiency and scalability across geographic regions.

RESEARCH TRIANGLE PARK, N.C. – April 5, 2022 – IQVIA™ (NYSE:IQV) today announced that Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has selected IQVIA’s safety and regulatory technology solutions. IQVIA’s Vigilance Platform and RIM Smart applications will enable Ferrer to scale for future growth by streamlining operations and improving efficiency of its safety and regulatory teams.

IQVIA offers modular safety, regulatory, and quality technology solutions that are specifically designed to meet the unique needs of medical device and pharmaceutical firms. Ferrer will benefit from the solutions’ easy rollout, automation of labor-heavy activities, and immediate boost in team efficiency.

“In looking to improve the excellence of our current operations and to continuously improve compliance levels, we assessed a field of providers that had the life sciences industry expertise along with technical vision that could grow with us as we increase our operational capacity,” said Silvia Martín, chief quality, regulatory and pharmacovigilance officer for Ferrer. “We determined IQVIA’s IVP and RIM Smart solutions would help ensure we remain compliant with regulatory agencies across our geographic regions and improve the operational excellence of our processes by automating many manually intensive tasks.”

The IQVIA Vigilance Platform (IVP) simplifies and automates safety and surveillance processes while boosting speed, accuracy, and efficiency. IVP runs in IQVIA’s secure SaaS environment using proprietary artificial intelligence, machine learning and natural language processing algorithms. It delivers insights that improve compliance and product safety while adding value in the product development process. IQVIA RIM Smart complements the IVP platform as a modern regulatory information management solution. It’s built to increase speed, collaboration, efficiency, and visibility across a client’s global portfolio. RIM Smart provides interconnected, comprehensive and intelligence management of the entire regulatory process.

“Our collaboration with Ferrer underscores our commitment to helping life sciences firms address their increasingly complex safety and regulatory needs,” said Joe Rymsza, vice president, IQVIA Safety, Regulatory and Quality Technology Solutions. “By leveraging IVP and RIM Smart, Ferrer will create the foundation for optimizing their safety and regulatory operations.”

 

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 79,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com

 

Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Source: IQVIA

Contact Us